The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1b/2, safety lead-in and dose-expansion trial of ivosidenib plus durvalumab and gemcitabine/cisplatin as first-line therapy in patients with locally advanced, unresectable or metastatic cholangiocarcinoma with an IDH1 mutation.
 
James Harding
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Cogent Medicine; Elevar Therapeutics; Exelixis; Jazz Pharmaceuticals; Merck; RayzeBio; SERVIER
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squibb Foundation (Inst); Jazz Pharmaceuticals (Inst); Kinnate Biopharma (Inst); Lilly (Inst); Tvardi Therapeutics (Inst); yivvia (Inst); Zymeworks (Inst)
 
Anthony El-Khoueiry
Honoraria - ABL Bio; Agenus; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Merck; QED Therapeutics; Qurient; Roche/Genentech; Senti Biosciences; SERVIER; Tallac Therapeutics, Inc.
Consulting or Advisory Role - ABL Bio; Agenus; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Gilead Sciences; Merck; Pieris Pharmaceuticals; QED Therapeutics; Qurient; Roche; Senti Biosciences; SERVIER; Tallac Therapeutics, Inc.
Research Funding - Astex Pharmaceuticals; AstraZeneca; Auransa; Fulgent Genetics
Travel, Accommodations, Expenses - Affimed Therapeutics
 
Makoto Ueno
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Incyte; J-pharma; MSD; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); Incyte (Inst); J-pharma (Inst); Jazz Pharmaceuticals (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Hong Jae Chon
Consulting or Advisory Role - Aptamer Sciences Inc; AstraZeneca; Bayer; BeiGene; BMS; Eisai; MSD; Ono Pharmaceutical; Roche; Sanofi; SERVIER
Speakers' Bureau - AstraZeneca; Bayer; BMS; Dong-A ST; Eisai; Roche; Sanofi; SERVIER
Research Funding - BeiGene (Inst); Boryung (Inst); Dong-A ST (Inst); Hanmi (Inst); inno-n (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Medivir (Inst)
 
Jin Won Kim
Consulting or Advisory Role - AstraZeneca; BeiGene Beijing; BeiGene Beijing; BeyondBIO; Bristol-Myers Squibb/Celgene; Eisai; GC Cell; MSD; Ono Pharmaceutical; Roche; Sanofi; Servier; TCUBEit
Research Funding - Boryung Pharmaceuticals; Samyang
 
Hye Jin Choi
No Relationships to Disclose
 
Myung Ah Lee
Consulting or Advisory Role - ElmediX; Green Cross; Roche; SERVIER; Yuhan
Speakers' Bureau - Yuhan
 
Valentine Barboux
Employment - SERVIER
 
Camelia Gliser
Employment - SERVIER
 
Nicole McNeer
Employment - AstraZeneca; Syndax
Stock and Other Ownership Interests - AstraZeneca; Syndax
Patents, Royalties, Other Intellectual Property - Compositions for enhancing targeted gene editing and methods of use thereof. Patent number: 11136597. Date: October 2021. Applicants: Yale University, Carnegie Mellon University. Inventors: W. Mark Saltzman, Peter Glazer, Raman Bahal, Nicole Ali McNeer, D
Travel, Accommodations, Expenses - AstraZeneca; Syndax
 
Do-Youn Oh
Consulting or Advisory Role - Abbvie; Alligtor Bioscience AB; Arcus Biosciences; ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Basilea; Bayer; BeiGene; Celgene; Eutilex; Genentech/Roche; Halozyme; Hana Pharm; Idience; IQVIA; J-Pharma; LG Chem; Merck Serono; Mirati Therapeutics; Moderna Therapeutics; MSD Oncology; Novartis; Taiho Pharmaceutical; Turning Point Therapeutics; Yuhan; Zymeworks
Research Funding - Array BioPharma; AstraZeneca; BeiGene; Handok; Lilly; MSD; Novartis; SERVIER